Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
NEW HAVEN, Conn., May 04, 2018 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018, at 9:20 a.m. ET at the Intercontinental Boston Hotel, Boston, MA.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its capabilities across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors & Media: Glenn Schulman, PharmD, MPH Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 [email protected]
